Nachrichten zur Karyopharm Therapeutics Inc. Aktie

Karyopharm wins FDA’s Orphan Drug status for leading asset in myelofibrosis

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm begins dosing in late-stage study of selinexor combo therapy for multiple myeloma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Karyopharm Therapeutics For: May 19

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm und Menarini Group erhalten positives CHMP-Gutachten für NEXPOVIO® (Selinexor) zur Behandlung von Patienten mit refraktärem Multiplem Myelom

Menarini Industrie Farmaceutiche Riunite: Newton, Massachusetts und Florenz, Italien (ots/PRNewswire) - -- Entscheidung der Europäischen Kommission in ca. 60 Tagen…

Karyopharm und Menarini Group erhalten positives CHMP-Gutachten für NEXPOVIO® (Selinexor) zur Behandlung von Patienten mit refraktärem Multiplem Myelom

-- Entscheidung der Europäischen Kommission in ca. 60 Tagen erwartet -- NEWTON, Massachusetts und FLORENZ, Italien, 22. Mai 2022 /PRNewswire/…

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy , May 20, 2022 /PRNewswire/…

Karyopharm, Menarini Get Positive CHMP Opinion for Nexpovio in Multiple Myeloma

Karyopharm, Menarini Get Positive CHMP Opinion for Nexpovio in Multiple Myeloma...…

Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference

NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer…

Insiderhandel: President and CEO verkauft Aktien von Karyopharm Therapeutics im Wert von 177.509$

Paulson, Richard A. - Vorstand - Tag der Transaktion: 2022-05-04...…

Karyopharm Therapeutics (KPTI) Q1 2022 Earnings Call Transcript

KPTI earnings call for the period ending March 31, 2022....…

Analyst Ratings for Karyopharm Therapeutics

Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter: Latest Ratings for KPTI …

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License…

Karyopharm Therapeutics Q1 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics Earnings Preview

Karyopharm Therapeutics (NASDAQ:KPTI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Heres what investors need to…

Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting

NEWTON, Mass., April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today…

Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference

NEWTON, Mass., April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,…

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., April 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,…

Form 8-K Karyopharm Therapeutics For: Mar 22

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics (KPTI) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer

Study Results to be Presented at the European Society of Medical Oncologys Virtual Plenary and the Society for Gynecologic Oncology…

Karyopharm Names New Head of Investor Relations

– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations –…

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi

Heres a roundup of top developments in the biotech space over the last 24 hours. read more...…

Why Are Karyopharm Shares Trading Lower Today

Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an read more...…

Karyopharm Shares Fall Premarket After Xpovio Setback in Endometrial Cancer >KPTI

Karyopharm Shares Fall Premarket After Xpovio Setback in Endometrial Cancer >KPTI...…

Form 10-K Karyopharm Therapeutics For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., Feb. 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,…

Why Are Karyopharm Shares Plunging Today?

Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities." read…

Karyopharm slips as medical chief steps down

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Thinking about buying stock in Creative Medical Technology, Nu Holdings, Barrick Gold, Opendoor Technologies, or Karyopharm Therapeutics?

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CELZ, NU, GOLD, OPEN, and KPTI. To…

Karyopharm spikes on cancelation of presentation at SVB Leerink conference

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference

NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,…

Why Karyopharm Therapeutics Stock Was a Winner on Wednesday

An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotechs stock....…

Insiderhandel: Aufsichtsrat verkauft Aktien von Karyopharm Therapeutics im Wert von 132.851$

Kauffman, Michael - Aufsichtsrat - Tag der Transaktion: 2022-02-07...…

Insiderhandel: EVP, CFO & Treasurer verkauft Aktien von Karyopharm Therapeutics im Wert von 38.925$

Mason, Michael - Vorstand - Tag der Transaktion: 2022-02-07...…

Insiderhandel: EVP, Chief Medical Officer verkauft Aktien von Karyopharm Therapeutics im Wert von 16.805$

Shah, Jatin - Vorstand - Tag der Transaktion: 2022-02-07...…

Insiderhandel: EVP, Chief Dev. Officer verkauft Aktien von Karyopharm Therapeutics im Wert von 19.635$

Frenkel, Ran - Vorstand - Tag der Transaktion: 2022-02-07...…

Karyopharm Therapeutics (KPTI) Q4 2021 Earnings Call Transcript

KPTI earnings call for the period ending December 31, 2021....…

Karyopharm Therapeutics (KPTI) CEO, Richard Paulson on Q 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Karyopharm Therapeutics Stock Is Falling Today

Fourth-quarter sales of Xpovio were encouraging, but top-line results from another trial were a little disappointing....…

Karyopharm Therapeutics Inc. 2022 Q4 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Haemonetics, Second Sight top healthcare gainers; Pulse, Karyopharm lead losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Karyopharm Therapeutics (KPTI) Tops Q4 Earnings and Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 215% and 125.56%, respectively, for the quarter ended December 2021. Do…

Recap: Karyopharm Therapeutics Q4 Earnings

Karyopharm Therapeutics (NASDAQ:KPTI) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Heres what investors need to…

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage…

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer

NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,…